Bria-LUNG+™: Immunotherapy for Lung Cancer
Latest Developments
About Bria-LUNG+™
Bria-LUNG+™ is our next-generation, off-the-shelf cellular immunotherapy candidate in preclinical development for lung cancer. It’s being designed to activate the immune system against lung cancer cells using an approach informed by our experience with Bria-IMT™ and our broader Bria-OTS+™ platform. Our goal is to develop a scalable, allogeneic cell therapy that may offer consistent product characteristics without the manufacturing delays associated with patient-specific therapies.
Lung cancer remains one of the most significant global health challenges, with limited long-term responses to existing therapies for many patients. By applying our platform to this area of high unmet need, we aim to advance a candidate that can support the body’s natural defenses through enhanced T cell engagement and targeted immune activation. Bria-LUNG+™ is being designed with features that reflect the evolving understanding of lung cancer immunogenicity and tumor microenvironment biology.
What Makes Bria-LUNG+™ Different, and Why It Matters
We are developing Bria-LUNG+™ to address several limitations of current lung cancer treatment options:
- Personalized with Off-the-shelf availability for rapid access and standardized product characteristics and enhanced efficacy
- Engineered features intended to support immune cell recognition of lung cancer cells
- Potential combination compatibility with existing treatment approaches, including checkpoint inhibitors and targeted therapy, subject to future clinical evaluation
- Alignment with the Bria-OTS+™ framework, enabling matching based on key biomarkers for optimized immune engagement
Bria-LUNG+™ reflects our commitment to advancing scalable and scientifically grounded approaches that may complement ongoing developments in lung cancer immunotherapy.
Who Might Benefit
Bria-LUNG+™ is being developed with the needs of patients across lung cancer subtypes in mind, including non-small cell lung cancer. We aim to support individuals who may require new options following standard therapies, as well as those who may benefit from off-the-shelf treatments that don’t rely on autologous cell collection.
Potential candidates for immunotherapy treatment often include patients whose disease biology suggests compatibility with immune-activation strategies or those participating in lung cancer clinical trials focused on emerging therapeutic approaches. As development continues, we’ll refine the intended patient populations based on preclinical findings and regulatory feedback.
Future Outlook and Key Milestones
Bria-LUNG+™ is scheduled to enter the clinic late in 2026
Bria-LUNG+™ and Our Mission
We’re committed to expanding access to innovative, off-the-shelf immunotherapies designed to address major unmet needs in oncology. Bria-LUNG+™ represents an important step in broadening our pipeline into lung cancer, building on our expertise in immunotherapy development and patient-first philosophy. By advancing candidates such as Bria-LUNG+™, we aim to help shape a future where safe and effective lung cancer treatment options become more widely available to the individuals who need them.